Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $8.06M rose 12.1% year over year, behind the +54.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 42.1% from the prior quarter. Over 3 fiscal years it compounded at +120.1% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +12.1% toward the trailing-twelve-month pace of +54.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 34.02M USD
- Year-over-year change
- +68.6%
- 4-year CAGR
- +105.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.02M | +68.6% |
| FY2024 | 2024-12-31 | 20.17M | +56.2% |
| FY2023 | 2023-12-31 | 12.91M | +304.7% |
| FY2022 | 2022-12-31 | 3.19M | +65.9% |
| FY2021 | 2021-12-31 | 1.92M | — |
Stock-Based Compensation vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's LTM Sep 2026 stock-based compensation of $41.68M is the 6th largest of the 11 companies compared; the peer median is $41.3M.
- Its year-over-year change of +54.1% is the 4th highest of 11, against a peer median of +5.8%.
- Over three fiscal years its annual growth of +120.1% compares with a peer median of +30.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.88M | -31.7% | +9.8% | 3.2% | |
| LTM Jun 2026 | $151.77M | +56.3% | +56.0% | — | |
| LTM Jul 2026 | $112.6M | +1.1% | +1.6% | 4.6% | |
| LTM Mar 2026 | $49.18M | +10.5% | +43.7% | 22.6% | |
| LTM Jun 2026 | $48.31M | -34.7% | +3.6% | 466.8% | |
| LTM Sep 2026 | $41.68M | +54.1% | +120.1% | — | |
| LTM Mar 2026 | $34.28M | -12.0% | +8.8% | — | |
| LTM Mar 2026 | $29.43M | +17.2% | +38.3% | — | |
| LTM Mar 2026 | $25.38M | +66.4% | — | — | |
| LTM Jun 2026 | $19.89M | -153.0% | +30.1% | 11.7% | |
| LTM Mar 2026 | $15.73M | +224.1% | +209.1% | — | |
| Peer median (excluding ELVN) | $41.3M | +5.8% | +30.1% | 11.7% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.74M) | (37.66M) | (71.58M) | (89.02M) | (103.69M) |
| Depreciation & Amortization | 115K | 215K | 297K | 317K | 263K |
| Deferred Income Tax | (3.81M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.92M | 3.19M | 12.91M | 20.17M | 34.02M |
| Change in Working Capital | 3.57M | 438K | 1.4M | (4.54M) | (1.12M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | 411K | (2.25M) | 810K | 817K |
| Other Working Capital | 1.83M | 27K | 3.65M | (5.35M) | (1.94M) |
| Other Non-Cash Items | 3.81M | 1.74M | (4.3M) | (118K) | 232K |
| Operating Cash Flow | (19.13M) | (32.08M) | (61.27M) | (73.19M) | (70.3M) |
| Capital Expenditures | (191K) | (612K) | (149K) | (44K) | (158K) |
| Acquisitions (Net) | 0 | 35M | 0 | 0 | 0 |
| Purchases of Investments | (47.56M) | (35M) | (268.26M) | (350.74M) | (446.79M) |
| Sales of Investments | 45.94M | 41.88M | 120M | 313.91M | 272.9M |
| Other Investing Activities | 1.62M | (41.88M) | 0 | 873K | 213K |
| Investing Cash Flow | (191K) | (612K) | (148.41M) | (36M) | (173.84M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (1.02M) | (1.23M) | 161.2M | 39.19M | 218.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (566K) | 73.09M | 93.98M | 0 |
| Financing Cash Flow | (1.02M) | (1.8M) | 234.29M | 133.17M | 218.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (20.34M) | (34.49M) | 24.61M | 23.98M | (25.28M) |
| Free Cash Flow | (19.33M) | (32.69M) | (61.42M) | (73.24M) | (70.46M) |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.